Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion

Molecular Cancer Therapeutics

Volumn 4, Issue 11, 2005, Pages 1717-1728

  Kaliski, Alexandre ^a   Maggiorella, Laurence ^b   Cengel, Keith A ^b   Mathe, Denis ^a   Rouffiac, Valerie ^a   Opolon, Paule ^a   Lassau, Nathalie ^a   Bourhis, Jean ^a   Deutsch, Eric ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; ANTINEOPLASTIC AGENT; GELATINASE A; MATRIGEL; MATRIX METALLOPROTEINASE INHIBITOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL ADHESION; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; DOPPLER FLOWMETRY; DOWNSTREAM PROCESSING; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; GENE ACTIVATION; GROWTH INHIBITION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; IONIZING RADIATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION; THROMBOCYTE; TUMOR GROWTH; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COLLAGEN; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; LAMININ; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOPLASMS, RADIATION-INDUCED; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PROTEOGLYCANS; RADIATION, IONIZING; TIME FACTORS; ULTRASONOGRAPHY; ULTRASONOGRAPHY, DOPPLER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 28044461236     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0179     Document Type: Article

References (52)

1. Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 2004;22:1926-33.
2. McKenna WG, Muschel RJ. Targeting tumor cells by enhancing radiation sensitivity. Genes Chromosomes Cancer 2003;38:330-8.
3. Garzotto M, Haimovitz-Friedman A, Liao W, et al. Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res 1999;59:5194-201.
4. Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-70.
5. Yuan ZM, Huang Y, Ishiko T, Kharbanda S, Weichselbaum R, Kufe D. Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase. Proc Natl Acad Sci U S A 1997;94:1437-40.
6. Gupta AK, Bakanauskas VJ, Cerniglia GJ, et al. The Ras radiation resistance pathway. Cancer Res 2001;61:4278-82.
7. McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 2003;22:5866-75.
8. Yao SL, Akhtar AJ, McKenna KA, et al. Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat Med 1996;2:1140-3.
9. 2 arrest after DNA damage. Science 1998;282: 1497-501.
10. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003;22:7486-95.
11. Brown JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002;1:453-8.
12. Cook JA, Gius D, Wink DA, Krishna MC, Russo A, Mitchell JB. Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol 2004;14:259-66.
13. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003;9: 1957-71.
14. Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer 2004;4:737-47.
15. Matrisian LM. The matrix-degrading metalloproteinases. Bioessays 1992;14:455-63.
16. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
17. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277:225-8.
18. Levi E, Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci U S A 1996;93: 7069-74.
19. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2:737-44.
20. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991;2: 297-321.
21. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002;20: 153-9.
22. Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin Ther Targets 2003; 7:385-97.
23. Syed S, Takimoto C, Hidalgo M, et al. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res 2004; 10:6512-21.
24. Ramnath N, Creaven PJ. Matrix metalloproteinase inhibitors. Curr Oncol Rep 2004;6:96-102.
25. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000;19: 6642-50.
26. Hanahan D. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985;315:115-22.
27. Sternlicht MD, Bergers G. Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects. Emerg Ther Targets 2000;4:609-33.
28. Langdon SP, Hendriks HR, Braakhuis BJ, et al. Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study. Ann Oncol 1994;5:415-22.
29. Lassau N, Paturel-Asselin C, Guinebretiere JM, et al. New hemodynamic approach to angiogenesis: color and pulsed Doppler ultrasonography. Invest Radiol 1999;34:194-8.
30. Lassau N, Koscielny S, Avril MF, et al. Prognostic value of angiogenesis evaluated with high-frequency and color Doppler sonography for preoperative assessment of melanomas. AJR Am J Roentgenol 2002; 178:1547-51.
31. Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 2001;61:2744-50.
32. Qian LW, Mizumoto K, Urashima T, et al. Radiation-induced increase in invasive potential of human pancreatic cancer cells and its blockade by a matrix metalloproteinase inhibitor, CGS27023. Clin Cancer Res 2002;8: 1223-7.
33. Gehrmann ML, Douglas JT, Banyai L, Tordai H, Patthy L, Llinas M. Modular autonomy, ligand specificity, and functional cooperativity of the three in-tandem fibronectin type II repeats from human matrix metalloproteinase 2. J Biol Chem 2004;279:46921-9.
34. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-8.
35. Belotti D, Paganoni P, Manenti L, et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003;63:5224-9.
36. Brown CK, Khodarev NN, Yu J, et al. Glioblastoma cells block radiation-induced programmed cell death of endothelial cells. FEBS Lett 2004;565:167-70.
37. Gupta VK, Jaskowiak NT, Beckett MA, et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 2002;8:47-54.
38. Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23: 709-17.
39. Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000; 106:511-21.
40. Tang Y, Nakada MT, Kesavan P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 2005;65:3193-9.
41. Rybak SM, Sanovich E, Hollingshead MG, et al. "Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies. Cancer Res 2003;63: 2812-9.
42. Niermann KJ, Fleischer AC, Donnelly EF, Schueneman AJ, Geng L, Hallahan DE. Sonographic depiction of changes of tumor vascularity in response to various therapies. Ultrasound Q 2005;21:61-7.
43. Kwei S, Stavrakis G, Takahas M, et al. Early adaptive responses of the vascular wall during venous arterialization in mice. Am J Pathol 2004; 164:81-9.
44. Isaka N, Padera TP, Hagendoorn J, Fukumura D, Jain RK. Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res 2004;64:4400-4.
45. Patel RN, Attur MG, Dave MN, et al. A novel mechanism of action of chemically modified tetracyclines: inhibition of COX-2-mediated prostaglandin E2 production. J Immunol 1999;163:3459-67.
46. Ansiaux R, Baudelet C, Jordan BF, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005;11:743-50.
47. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A 2003;100: 2645-50.
48. Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998;394: 287-91.
49. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300: 1155-9.
50. Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001;61:2413-9.
51. Ferrario A, Chantrain CF, von Tiehl K, et al. The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res 2004;64: 2328-32.
52. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.